<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144561">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840085</url>
  </required_header>
  <id_info>
    <org_study_id>DSC127-2012-05</org_study_id>
    <nct_id>NCT01840085</nct_id>
  </id_info>
  <brief_title>Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use</brief_title>
  <acronym>STRIDE 5</acronym>
  <official_title>Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers (&quot;DFU&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derma Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derma Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study is designed to assess the chronic-use safety of 0.03% DSC127 gel
      administered on a once daily basis for up to 12 weeks per treatment period, potentially over
      multiple treatment periods with 4-week wash-out periods between treatment periods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of up to 4 different periods for each individual subject over the
      duration of the study:

      A screening period, treatment periods consisting of the administration of DSC127 for up to
      12 weeks, a washout period between treatment periods, and an observation period.

      All subjects will complete the screening period and one or more of the other periods
      depending on the presence or absence of one or more ulcers, and the possible recurrence
      thereof.  If ulcers heal during the treatment period the subjects will continue to be
      followed bi-weekly via phone call for follow-up.  If during the follow-up (observation)
      period ulcers recur or new ones appear which qualify the subject to enter a new treatment
      cycle, a clinic visit is scheduled and a new treatment period begins.  Subjects with
      qualifying ulcers may complete as many treatment and washout periods as required during the
      study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of all subjects reporting Adverse Events and Serious Adverse Events related to study treatment</measure>
    <time_frame>2.5yrs</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Changes from baseline in laboratory evaluations (clinically significant changes)</measure>
    <time_frame>2.5yrs</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of all subjects treated and terminating prematurely due to adverse events related to study treatment.</measure>
    <time_frame>2.5yrs</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>0.03% DSC127 topical gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.03% DSC127 topical gel</intervention_name>
    <arm_group_label>0.03% DSC127 topical gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ambulatory subjects who are at least 18 years of age at screening

          -  Subjects may be enrolled with or without active ulcers.

        Subjects with active ulcers at the start of the Screening Period and upon enrollment into
        the study, are required to have at least one chronic healing or non-healing Wagner Grade 1
        or Grade 2 ulcer that fulfills all criteria.  Subjects without active ulcers at the start
        of the Screening Period and upon enrollment into the study are required to have originated
        from a prior DSC127 study.

          -  Have an ankle-brachial index (ABI) &gt; 0.8 for neuropathic DFU, or have a
             transcutaneous oxygen pressure (TcPO2) &gt; 40 mm Hg or great toe systolic pressure &gt; 50
             mmHg to ensure healing potential.

          -  Have Type I or Type II diabetes under metabolic control as confirmed by a
             glycosylated hemoglobin (HbA1c) of ≤ 14%, and a serum creatinine level of ≤ 3mg/dL
             obtained at enrollment or within 3 months of study enrollment.

          -  Female subjects of child-bearing potential must have negative pregnancy test at the
             time of enrollment and at the initiation of each study treatment period.

          -  Female subjects of child-bearing potential must be willing to use a medically
             acceptable method of birth control during the treatment  periods of study
             participation.

          -  Ability and willingness to understand and comply with study procedures and to give
             written informed consent prior to enrollment in the study or initiation of study
             procedures

        Exclusion Criteria:

          -  Has a known hypersensitivity to any of the study medication components.

          -  Exposure to any investigational agent within 28 days of entry into study.

          -  Has active malignant disease of any kind (with the exception of basal cell
             carcinoma). A subject, who has had a malignant disease in the past, was treated and
             is currently disease-free, may be considered for study entry. Disease-free is defined
             as in remission for at least 5 years.

          -  Chronic liver dysfunction evidenced by transaminase levels &gt; 2.5 times higher than
             the upper level of normal on two occasions.

          -  Has a history of additional risk factors for torsade de pointes (TdP) (eg. heart
             failure, hypokalemia, family history of Long QT Syndrome) or taking medication which
             are known to prolong QT/QTc (Appendix G)

          -  Receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy.

          -  Prior radiation therapy of the foot with the ulcer under study.

          -  Current use of systemic corticosteroids or immunosuppressants within 8 weeks prior to
             enrollment into the study

          -  Sickle-cell anemia, Raynaud's or other peripheral vascular disease.

          -  Subjects receiving a biologic agent to include growth factors and skin equivalents
             (Regranex, Apligraft, or Dermagraft) in the 7 days prior to exposure to DSC127.

          -  Subject who, in the opinion of the investigator, has uncontrolled hypertension

          -  Subject has an ulcer which is determined to be clinically infected and requires
             antimicrobials or agents known to affect wound healing or has been taking systemic
             antibiotics for more than 7 days for any reason. (Subjects with infection at the
             initial visit of the Screening Period can be re-screened three weeks later after a
             single course of antibiotic therapy; if after that time infection is still present,
             the subject will be excluded.)

          -  Subjects who, in the opinion of the investigator, have clinically significant anemia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gere diZerega, MD</last_name>
    <role>Study Director</role>
    <affiliation>Derma Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelagh Verco, PhD</last_name>
    <phone>805-704-1179</phone>
    <email>sverco@dermasciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Physician's Resource Group</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Walker</last_name>
      <phone>334-403-7083</phone>
      <email>Jimwalker74@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Cody, LPN, CCRC</last_name>
      <phone>334-403-7083</phone>
      <email>beverlycd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Todd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WILMAX Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Brown</last_name>
      <phone>251-340-6970</phone>
      <email>ceo@wilmax.com</email>
    </contact>
    <contact_backup>
      <last_name>Candance Jenkins</last_name>
      <phone>251-340-6970</phone>
      <email>candace@wilmax.com</email>
    </contact_backup>
    <investigator>
      <last_name>William Higgs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jenkins</last_name>
      <phone>870-219-9865</phone>
      <email>david.jenkins@neabaptistclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Graf</last_name>
      <phone>870-219-9865</phone>
      <email>Brenda.graf@neabaptistclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Fletcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roy O. Kroeker, DMP, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Kroeker</last_name>
      <phone>559-436-8162</phone>
      <email>mem-k@pacbell.net</email>
    </contact>
    <investigator>
      <last_name>Roy Kroeker, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suni Allen</last_name>
      <phone>213-365-0793</phone>
      <email>sunigmka@aol.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sigal, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Farley</last_name>
      <phone>818-364-3796</phone>
      <email>mefarley@dhs.lacounty.gov</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Arriaga</last_name>
      <phone>818-364-4073</phone>
      <email>warriaga@dhs.lacounty.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Balingit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madonna Nicolai, RN</last_name>
      <phone>714-550-9990</phone>
      <email>madonna.nicolai@ocresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Joel Neutel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Wound Management Clinic / Joseph M. Still Burn and Wound Clinic</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farrah Parker</last_name>
      <phone>706-364-2966</phone>
      <email>farrah.parker@jmsburncenters.com</email>
    </contact>
    <investigator>
      <last_name>S.M. Abu Zaheed Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Osh and Associates Foot &amp; Leg Clinic/ APSMO</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigi Villareal</last_name>
      <phone>678-852-1355</phone>
      <email>apsmo.crc.osh.footleg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evaristus Oshiokpekhai, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lafayette Regional Research Group</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Bell</last_name>
      <phone>765-807-2770</phone>
      <email>bbell@unityhc.com</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Williams</last_name>
      <phone>765-807-2770</phone>
      <email>swilliams@unityhc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marlin Schul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson City Medical Group</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Webb</last_name>
      <phone>573-556-7785</phone>
      <phone_ext>2</phone_ext>
      <email>dwebb@jcmg.org</email>
    </contact>
    <investigator>
      <last_name>Jody McAleer, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Moore</last_name>
      <phone>816-271-6718</phone>
      <email>bob.moore@heartland-health.com</email>
    </contact>
    <investigator>
      <last_name>Steven Orr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Foot &amp; Ankle Specialists</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Lennon</last_name>
      <phone>252-830-1000</phone>
      <email>christylennon@embargmail.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Gauland, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brettany Holt</last_name>
      <phone>910-815-6108</phone>
      <email>bholt@pmg-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Leah Workman</last_name>
      <phone>910-815-6108</phone>
      <email>lworkman@pmg-research.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Dzurik, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wound Institute and Research Center</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanci Dobson, RN, CCRP</last_name>
      <phone>570-961-8000</phone>
      <email>ndobsonrn@managewounds.com</email>
    </contact>
    <investigator>
      <last_name>Michael Moore, MD, FACS,FACCWS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Musculoskeletal Institute</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Sonderegger</last_name>
      <phone>803-649-3668</phone>
      <phone_ext>1016</phone_ext>
      <email>sams@cmi.md</email>
    </contact>
    <investigator>
      <last_name>Mackie Walker, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forth Worth Diagnostic Clinic</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Bolling</last_name>
      <phone>817-992-2372</phone>
      <email>debo322@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcy Conner</last_name>
      <phone>817-992-2372</phone>
      <email>marcysconner@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Byron Conner, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westbury Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereyda Nolasco</last_name>
      <phone>713-777-5343</phone>
      <email>nnolasco@mercurycr.us.com</email>
    </contact>
    <investigator>
      <last_name>Alan Nolasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic foot ulcer</keyword>
  <keyword>plantar neuropathic ulcer</keyword>
  <keyword>plantar neuroischemic ulcer</keyword>
  <keyword>Wagner Grade 1 or Grade 2 DFU</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
